Treatment expectations and patient-reported outcomes of nusinersen therapy in adult spinal muscular atrophy

BACKGROUND: The antisense-oligonucleotide (ASO) nusinersen has recently been approved as the first genetically modifying therapy for 5q-associated spinal muscular atrophy (SMA) based on randomized sham-controlled trials in infants and children. The efficacy in adults with long disease history and ad...

Descripción completa

Detalles Bibliográficos
Autores principales: Osmanovic, Alma, Ranxha, Gresa, Kumpe, Mareike, Müschen, Lars, Binz, Camilla, Wiehler, Flavia, Paracka, Lejla, Körner, Sonja, Kollewe, Katja, Petri, Susanne, Schreiber-Katz, Olivia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Original Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7359174/
https://www.ncbi.nlm.nih.gov/pubmed/32361837
http://dx.doi.org/10.1007/s00415-020-09847-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7359174/
https://www.ncbi.nlm.nih.gov/pubmed/32361837
http://dx.doi.org/10.1007/s00415-020-09847-8

Ejemplares similares